Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14440MR)

This product GTTS-WQ14440MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14440MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12786MR IVTScrip™ mRNA-Anti-NOTCH2&NOTCH3, OMP-59R5(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-59R5
GTTS-WQ627MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ10210MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LDP-02
GTTS-WQ1995MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ8517MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Hu3F8
GTTS-WQ5762MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ11348MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ4398MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-224818
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW